Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Identification of SSEA-1 expressing enhanced reprogramming (SEER) cells in porcine embryonic fibroblasts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ELMO3: a direct driver of cancer metastasis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Keeping each other in check: a reciprocal relationship between cytokines and miRNA

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Contact allergy in Danish children: Current trends

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A prospective 52-week randomized controlled trial of patient-initiated care consultations for patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of pediatric atopic dermatitis following thymectomy: A Danish register study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The pathogenesis of cutaneous T-cell lymphoma (CTCL) remains elusive. Recent discoveries indicate that the oncogenic microRNA miR-155 is overexpressed in affected skin from CTCL patients. Here, we address what drives the expression of miR-155 and investigate its role in the pathogenesis of CTCL. We show that malignant T cells constitutively express high levels of miR-155 and its host gene BIC (B cell integration cluster). Using ChIP-seq, we identify BIC as a target of transcription factor STAT5, which is aberrantly activated in malignant T cells and induced by IL-2/IL-15 in non-malignant T cells. Incubation with JAK inhibitor or siRNA-mediated knockdown of STAT5 decreases BIC/miR-155 expression, whereas IL-2 and IL-15 increase their expression in cell lines and primary cells. In contrast, knockdown of STAT3 has no effect, and BIC is not a transcriptional target of STAT3, indicating that regulation of BIC/miR-155 expression by STAT5 is highly specific. Malignant proliferation is significantly inhibited by an antisense-miR-155 as well as by knockdown of STAT5 and BIC.   In conclusion, we provide the first evidence that STAT5 drives expression of oncogenic BIC/miR-155 in cancer. Moreover, our data indicate that the STAT5/BIC/miR-155 pathway promotes proliferation of malignant T cells, and therefore is a putative target for therapy in CTCL.
Original languageEnglish
JournalCell cycle (Georgetown, Tex.)
Volume12
Issue number12
Pages (from-to)1939-47
Number of pages9
DOIs
StatePublished - 15 Jun 2013

ID: 38986955